Compare Cardinal Health Inc (CAH) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cardinal Health Inc vs Ryanair Holdings plc — how do they compare? Cardinal Health Inc trades at $234.2 (market cap $55.88B), while Ryanair Holdings plc trades at $59.4 (market cap $29.63B). The key difference: Cardinal Health Inc is the larger of the two by market cap, and Ryanair Holdings plc pays the higher dividend (1.51%). Which is the better fit depends on your goals.
| CAH | RYAAY | |
|---|---|---|
Market Cap | $55.88B | $29.63B |
Sector | Health | Industrials |
52-Week High | $240.26 | $73.82 |
52-Week Low | $146.04 | $53.24 |
Enterprise Value | $59.91B | $26.61B |
Dividend Yield | 0.86% | 1.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cardinal Health (CAH) trades at $235.3, down 0.79% on the day, but remains near its 52-week high. The stock exhibits a bullish technical signal with consistent earnings beats in recent quarters, including Q2 2026 EPS of $2.91 versus $2.42 expected. Revenue for fiscal 2025 was $222.58 billion, with net income reaching $1.56 billion. Analyst consensus is strongly positive, with 18 buys and a $266.43 price target, reflecting confidence in the company's pharmaceutical and specialty business growth.
The outlook for CAH is favorable, driven by robust earnings performance and optimistic fiscal 2027 guidance. Key opportunities include sustained demand for specialty drugs and operational efficiency gains. Risks involve high debt levels, with a debt-to-asset ratio of 16.09 in 2025, and competitive pressures in the healthcare distribution sector. Investors should weigh strong analyst support against balance sheet leverage and market volatility.
RYAAY trades at $59.36, down 0.25% on the day, with a bearish technical signal. The company reported mixed quarterly earnings, missing Q4 2025 and Q2 2026 EPS estimates but beating in Q1 2026. Fundamentals show strong profitability with a 12.13% net margin and attractive valuation with a P/E of 14.37. Recent news highlights a strategic AI partnership with Google Cloud and industry challenges from lower fares and fuel costs.
The outlook is balanced; analyst consensus is bullish (62.5% buy ratings), but near-term headwinds from fare pressure and geopolitical risks persist. The stock offers value based on earnings, though operational volatility and competitive dynamics require monitoring for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
